These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 12412532)
21. Oxaliplatin in the treatment of colorectal cancer. Kim GP; Erlichman C Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157 [TBL] [Abstract][Full Text] [Related]
22. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. Grothey A; Sargent DJ J Clin Oncol; 2005 May; 23(15):3311-3. PubMed ID: 15908645 [No Abstract] [Full Text] [Related]
23. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. Meyer L; Zuberbier T; Worm M; Oettle H; Riess H J Clin Oncol; 2002 Feb; 20(4):1146-7. PubMed ID: 11844841 [No Abstract] [Full Text] [Related]
25. Cancer drug approval in the United States, Europe, and Japan. Milsted RA Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686 [No Abstract] [Full Text] [Related]
27. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? Schilsky RL J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701 [No Abstract] [Full Text] [Related]
29. Satraplatin: an orally available platinum analog for the treatment of cancer. Choy H Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070 [TBL] [Abstract][Full Text] [Related]
32. [Results of a phase-I clinical study of carboplatin--(cyclobutane-1,1-dicarboxylate)diamineplatinum (II)]. Gorbunova VA Vestn Akad Med Nauk SSSR; 1986; (5):45-7. PubMed ID: 3524054 [No Abstract] [Full Text] [Related]
33. Limited activity of carboplatin in malignant lymphoma. Danieu L; Warrell RP Cancer Treat Rep; 1986 Jul; 70(7):931-2. PubMed ID: 3521851 [No Abstract] [Full Text] [Related]
37. Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity? Sebagh M; Plasse M; Lévi F; Adam R Ann Oncol; 2005 Feb; 16(2):331; author reply 332-3. PubMed ID: 15668292 [No Abstract] [Full Text] [Related]
38. Drug approval triggers debate on future direction for cancer treatments. Frantz S Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324 [No Abstract] [Full Text] [Related]
39. Serious delayed hypersensitivity reaction to oxaliplatin. de Vries RS; Mattijssen EJ; van Sorge AA Ann Oncol; 2006 Nov; 17(11):1723-4. PubMed ID: 16757568 [No Abstract] [Full Text] [Related]
40. [Iproplatin--advantages and disadvantages of a new platinum cytostatic agent]. Hejl J; Hejlová N Cas Lek Cesk; 1988 Apr; 127(15):467-70. PubMed ID: 3378253 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]